Key Points
- EVP Paul Mahon sold 8,300 UTHR shares on March 19 at an average $529.95 for about $4.40M, cutting his stake by 15.52% to 45,172 shares (≈$23.94M).
- United Therapeutics beat EPS expectations with $7.70 (vs. $6.78) but slightly missed revenue forecasts at $790.2M, and analysts have largely raised targets—consensus is a "Moderate Buy" with an average price target of ~$548.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $529.95, for a total transaction of $4,398,585.00. Following the transaction, the executive vice president owned 45,172 shares of the company's stock, valued at approximately $23,938,901.40. The trade was a 15.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
United Therapeutics Stock Performance
Shares of UTHR stock opened at $527.00 on Friday. The firm has a market cap of $23.10 billion, a price-to-earnings ratio of 18.89, a P/E/G ratio of 1.91 and a beta of 0.84. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $548.12. The firm's 50-day simple moving average is $489.57 and its two-hundred day simple moving average is $466.41.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping analysts' consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company had revenue of $790.20 million for the quarter, compared to analysts' expectations of $814.80 million. During the same quarter in the previous year, the firm posted $6.19 EPS. United Therapeutics's revenue was up 7.4% on a year-over-year basis. Analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.
Hedge Funds Weigh In On United Therapeutics
Institutional investors have recently added to or reduced their stakes in the business. Geneos Wealth Management Inc. boosted its position in shares of United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after acquiring an additional 85 shares during the last quarter. Allworth Financial LP lifted its position in United Therapeutics by 147.2% during the second quarter. Allworth Financial LP now owns 356 shares of the biotechnology company's stock valued at $102,000 after purchasing an additional 212 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in United Therapeutics by 8.6% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 11,589 shares of the biotechnology company's stock worth $3,330,000 after buying an additional 917 shares in the last quarter. Creative Planning increased its holdings in shares of United Therapeutics by 10.1% in the 2nd quarter. Creative Planning now owns 4,270 shares of the biotechnology company's stock worth $1,227,000 after buying an additional 392 shares during the last quarter. Finally, Seizert Capital Partners LLC lifted its holdings in shares of United Therapeutics by 2.9% during the 2nd quarter. Seizert Capital Partners LLC now owns 125,541 shares of the biotechnology company's stock worth $36,074,000 after acquiring an additional 3,571 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
UTHR has been the topic of several research reports. Cantor Fitzgerald boosted their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the company an "overweight" rating in a research report on Thursday, March 12th. UBS Group increased their price objective on United Therapeutics from $655.00 to $705.00 and gave the stock a "buy" rating in a report on Thursday, March 5th. Oppenheimer lifted their target price on United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a report on Thursday, February 26th. TD Cowen increased their price target on shares of United Therapeutics from $525.00 to $575.00 and gave the stock a "buy" rating in a report on Wednesday, February 25th. Finally, HC Wainwright boosted their price objective on shares of United Therapeutics from $525.00 to $600.00 and gave the company a "buy" rating in a research note on Thursday, February 26th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, United Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $548.09.
Check Out Our Latest Research Report on United Therapeutics
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
